Victoza (liraglutide) NDC 0169-4060

NDC codes

FDA NDC Directory

Product NDC (as listed)0169-4060Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00169-4060Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0169-4060-12	00169406012	2 SYRINGE, PLASTIC in 1 CARTON (0169-4060-12) / 3 mL in 1 SYRINGE, PLASTICMarketed from Jan 25, 2010
0169-4060-13	00169406013	3 SYRINGE, PLASTIC in 1 CARTON (0169-4060-13) / 3 mL in 1 SYRINGE, PLASTICMarketed from Jan 25, 2010
0169-4060-90	00169406090	1 SYRINGE, PLASTIC in 1 CARTON (0169-4060-90) / 3 mL in 1 SYRINGE, PLASTICMarketed from Jan 25, 2010 · Sample package
0169-4060-99	00169406099	1 SYRINGE, PLASTIC in 1 CARTON (0169-4060-99) / 3 mL in 1 SYRINGE, PLASTICMarketed from Feb 13, 2015 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Victoza
Generic name (nonproprietary): liraglutide
Active ingredients: Liraglutide — 6 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Novo Nordisk
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022341
Marketing start: Jan 25, 2010
Listing expires: Dec 31, 2026
Other FDA classes: Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
Identifiers: Product ID 0169-4060_0d10d10e-0fe0-47ee-b9da-628e34907e98SPL ID 0d10d10e-0fe0-47ee-b9da-628e34907e98SPL set ID 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4RxCUI 897122, 897126UNII 839I73S42A
Pharmacologic class: GLP-1 Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400169406012 followed by a unit qualifier and the quantity

Package 00169-4060-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 14, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use: VICTOZA contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022341

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022341
Product	Strength	Form · route	Labeler	Product NDC
Victozaliraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	A-S Medication Solutions	50090-4503
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	A-S Medication Solutions	50090-7501
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Teva Pharmaceuticals USA, Inc.	0480-3667
Victozaliraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	A-S Medication Solutions	50090-2853